Clinical Research Directory
Browse clinical research sites, groups, and studies.
N-Acetylcysteine as Adjuvant Therapy for Drug-Induced Hepatitis in Hospitalized Tuberculosis Patients
Sponsor: RSUP Persahabatan
Summary
Anti-tuberculosis drug-induced liver injury (AT-DILI) is a common side effect of tuberculosis (TB) treatment. It often forces TB drugs to be stopped temporarily, which may reduce treatment success. N-acetylcysteine (NAC) is an antioxidant that helps the body make glutathione and may help the liver recover. Most previous studies tested NAC to prevent liver injury rather than to treat liver injury that has already occurred. This study aimed to find out whether oral NAC, given as an adjuvant therapy, improves liver function and nausea-vomiting in hospitalized adults with drug-susceptible TB who developed AT-DILI. Participants were randomly assigned to receive effervescent NAC 600 mg twice daily for 7 days or no NAC. Liver tests (ALT, AST, and total bilirubin) were measured on days 0, 3, 6, and 9, and nausea and vomiting were assessed daily from day 0 to day 9.
Official title: Efficacy of N-Acetylcysteine as Adjuvant Therapy for Drug-Induced Hepatitis in Hospitalized Tuberculosis Patients at Persahabatan Hospital, Jakarta
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
28
Start Date
2026-02-01
Completion Date
2026-09-30
Last Updated
2026-11-20
Healthy Volunteers
No
Conditions
Interventions
N-acetylcysteine (NAC)
Effervescent N-acetylcysteine 600 mg tablet, taken orally twice daily (2 × 600 mg) for 7 days.
Locations (1)
Persahabatan National Respiratory Referral Hospital
Jakarta, DKI Jakarta, Indonesia